Calixa Therapeutics, a biopharmaceutical company, develops a novel cephalosporin to address the problem of multi-drug resistant organisms.
Business Model:
Revenue: $0
Employees: 0-0
Address:
City: San Mateo
State: California
Zip:
Country: United States
Calixa Therapeutics, Inc. is a privately-held biopharmaceutical company focused on the development of a novel cephalosporin to address the expanding problem of multi-drug resistant organisms. Treatment of infections caused by resistant gram-negative bacteria, especially Pseudomonas aeruginosa, is recognized as an unmet medical need by the infectious diseases community. Calixa’s lead product, CXA-101, is an IV formulation of a novel cephalosporin that has excellent potency especially against multi-drug resistant Pseudomonas aeruginosa, which differentiates it from other cephalosporins. No similar drug is known to be in development. Calixa plans to combine this product with a β-lactamase inhibitor; the combination product (CXA-201) has the potential to become the first-line therapeutic choice for hospitalized patients suffering from serious infection caused by gram-negative organisms.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 1/2007 | Funding Round | 1 | - |
Frazier Healthcare Partners Frazier Healthcare Partners |
1/2007 | Funding Round | 1 | - |
Frazier Healthcare Partners Frazier Healthcare Partners |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|